BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26050922)

  • 1. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
    Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
    Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
    Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
    Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.
    Elias KM; Emori MM; Papp E; MacDuffie E; Konecny GE; Velculescu VE; Drapkin R
    Gynecol Oncol; 2015 Oct; 139(1):97-103. PubMed ID: 26321251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
    De Haven Brandon A; Box G; Hallsworth A; Court W; Matthews N; Herodek B; Arteagabeitia AB; Valenti M; Kirkin V
    Sci Rep; 2020 Jul; 10(1):10799. PubMed ID: 32612269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
    Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
    Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
    McKnight R; Cohen C; Siddiqui MT
    Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
    Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
    Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.
    Kaweesa EN; Bazioli JM; Pierre HC; Lantvit DD; Kulp SK; Hill KL; Phelps MA; Coss CC; Fuchs JR; Pearce CJ; Oberlies NH; Burdette JE
    Mol Pharm; 2023 Jun; 20(6):3049-3059. PubMed ID: 37155928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
    Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
    Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
    Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
    BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
    Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
    Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary.
    Sneha S; Nagare RP; Sidhanth C; Krishnapriya S; Garg M; Ramachandran B; Murhekar K; Sundersingh S; Ganesan TS
    Cell Oncol (Dordr); 2020 Aug; 43(4):601-616. PubMed ID: 32382997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.